All In Biotech

Drug Trial Radar · NCT07428499

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
ADARx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Conditions

  • Hereditary Angioedema (HAE)
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • HAE

Interventions

  • ADX-324 Dose Level 1Drug

    siRNA duplex oligonucleotide

  • ADX-324 Dose Level 2Drug

    siRNA duplex oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of ADX-324 in Participants with HAETime frame: Month 36

Locations

48 sites in 19 countries. Site status is shown where the registry gives one.

  • ADARx Clinical Site

    Litchfield Park, Arizona · Not yet recruiting

  • ADARx Clinical Site

    Little Rock, Arkansas · Not yet recruiting

  • ADARx Clinical Site

    San Diego, California · Not yet recruiting

  • ADARx Clinical Site

    Walnut Creek, California · Not yet recruiting

  • ADARx Clinical Site

    Orlando, Florida · Not yet recruiting

  • ADARx Clinical Site

    Chevy Chase, Maryland · Not yet recruiting

  • ADARx Clinical Site

    Wheaton, Maryland · Not yet recruiting

  • ADARx Clinical Site

    Detroit, Michigan · Not yet recruiting

  • ADARx Clinical Site

    St Louis, Missouri · Not yet recruiting

  • ADARx Clinical Site

    Las Vegas, Nevada · Recruiting

  • ADARx Clinical Site

    New York, New York · Recruiting

  • ADARx Clinical Site

    Cincinnati, Ohio · Not yet recruiting

  • ADARx Clinical Site

    Columbus, Ohio · Not yet recruiting

  • ADARx Clinical Site

    Toledo, Ohio · Not yet recruiting

  • ADARx Clinical Site

    Hershey, Pennsylvania · Not yet recruiting

  • ADARx Clinical Site

    Capital Federal, Buenos Aires, Argentina · Not yet recruiting

  • ADARx Clinical Site

    Buenos Aires, Buenos Aires F.D., Argentina · Not yet recruiting

  • ADARx Clinical Site

    Adelaide, South Australia, Australia · Not yet recruiting

  • ADARx Clinical Site

    Vienna, Austria · Not yet recruiting

  • ADARx Clinical Site

    Edegem, Antwerpen, Belgium · Not yet recruiting

  • ADARx Clinical Site

    Sofia, Bulgaria · Not yet recruiting

  • ADARx Clinical Site

    Edmonton, Alberta, Canada · Not yet recruiting

  • ADARx Clinical Site

    Ottawa, Ontario, Canada · Not yet recruiting

  • ADARx Clinical Site

    Montreal, Quebec, Canada · Not yet recruiting

  • ADARx Clinical Site

    Beijing, China · Not yet recruiting

  • ADARx Clinical Site

    Harbin, China · Not yet recruiting

  • ADARx Clinical Site

    Zhengzhou, China · Not yet recruiting

  • ADARx Clinical Site

    Split, Croatia · Not yet recruiting

  • ADARx Clinical Site

    Zagreb, Croatia · Not yet recruiting

  • ADARx Clinical Site

    Hradec Králové, Czechia · Recruiting

  • ADARx Clinical Site

    Prague, Czechia · Not yet recruiting

  • ADARx Clinical Site

    Montpellier, France · Not yet recruiting

  • ADARx Clinical Site

    Paris, France · Not yet recruiting

  • ADARx Clinical Site

    Nice, Alpes-Maritimes, France · Not yet recruiting

  • ADARx Clinical Site

    Tours, Indre-et-Loire, France · Not yet recruiting

  • ADARx Clinical Site

    Tübingen, Baden-Wurttemberg, Germany · Not yet recruiting

  • ADARx Clinical Site

    Hong Kong, Hong Kong · Not yet recruiting

  • ADARx Clinical Site

    Budapest, Hungary · Not yet recruiting

  • ADARx Clinical Site

    Ashkelon, Israel · Not yet recruiting

  • ADARx Clinical Site

    Tel Aviv, Israel · Not yet recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.